NTRK Alterations in Pediatric High-Risk Malignancies Identified Through European Clinical Sequencing Programs Constitute Promising Drug Targets

Affiliation

• ¹ Elke Pfaff, MD, Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany; Pediatric Glioma Research Group, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Pediatric Oncology, Hematology and Immunology, Heidelberg University Hospital, Heidelberg, Germany; Tiphaine Adam de Beaumais, MD, Clinical Research Department, Gustave Roussy Cancer Center, Villejuif, France; Antonin Marchais, PhD, Bioinformatics and INSERM U1015, Gustave Roussy Cancer Center, University Paris-Saclay, Villejuif, France; Cornelis M. van Tilburg, MD, Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany; Department of Pediatric Oncology, Hematology and Immunology, Heidelberg University Hospital, Heidelberg, Germany; Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany German Cancer Consortium (DKTK), Germany; KiTZ Clinical Trial Unit, Hopp Children's Cancer Center Heidelberg (KiTZ), German Cancer Research Center (DKFZ) and Heidelberg University Hospital, Heidelberg, Germany; Mirjam Blattner-Johnson, PhD, Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany; Pediatric Glioma Research Group, German Cancer Research Center (DKFZ), Heidelberg, Germany; Uta Dirksen, MD, German Cancer Consortium (DKTK), Partner Essen, Germany; University Hospital Essen, Pediatrics III, Hematology and Oncology, West German Cancer Centre, Essen, Germany; Ingrid 00D8ra, MD, PhD, Department of Pediatric Oncology and Hematology, Karolinska University Hospital, Solna, Sweden; Skane University Hospital, Lund, Sweden; Birgit Geoerger, MD, PhD, Department of Pediatric and Adolescent Oncology, Gustave Roussy Cancer Center, INSERM U1015, University Paris-Saclay, Villejuif, France; Gudrun Schleiermacher, MD, Equipe SiRIC RTOP Recherche Translationelle en Oncologie Pédiatrique, Institut Curie, Paris, France; SIREDO: Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer, Institut Curie, Paris, France; Stefan M. Pfister, MD, Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany; Department of Pediatric Oncology, Hematology and Immunology, Heidelberg University Hospital, Heidelberg, Germany; Division of Pediatric Neurooncology, German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany; Olaf Witt, MD, Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany; Department of Pediatric Oncology, Hematology and Immunology, Heidelberg University Hospital, Heidelberg, Germany; Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany; KiTZ Clinical Trial Unit, Hopp Children's Cancer Center Heidelberg (KiTZ), German Cancer Research Center (DKFZ) and Heidelberg University Hospital, Heidelberg, Germany; David T. W. Jones, PhD, Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany; Pediatric Glioma Research Group, German Cancer Research Center (DKFZ), Heidelberg, Germany; and Gilles Vassal, MD, PhD, Department of Pediatric and Adolescent Oncology, Gustave Roussy Cancer Center, Paris-Saclay University, Villejuif, France.